BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 26194553)

  • 1. Combined cytotoxic activity of an infectious, but non-replicative herpes simplex virus type 1 and plasmacytoid dendritic cells against tumour cells.
    Thomann S; Boscheinen JB; Vogel K; Knipe DM; DeLuca N; Gross S; Schuler-Thurner B; Schuster P; Schmidt B
    Immunology; 2015 Oct; 146(2):327-38. PubMed ID: 26194553
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the oncolytic activity of a replication-competent and a replication-deficient herpes simplex virus 1.
    Lindner G; Walter A; Magnus CL; Rosenhammer K; Holoborodko B; Koch V; Hirsch S; Grossmann L; Li S; Knipe DM; DeLuca N; Schuler-Thurner B; Gross S; Schwertner B; Toelge M; Rohrhofer A; Stöckl S; Bauer RJ; Knoll G; Ehrenschwender M; Haferkamp S; Schmidt B; Schuster P
    Immunology; 2024 Jun; 172(2):279-294. PubMed ID: 38444199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Both plasmacytoid dendritic cells and monocytes stimulate natural killer cells early during human herpes simplex virus type 1 infections.
    Vogel K; Thomann S; Vogel B; Schuster P; Schmidt B
    Immunology; 2014 Dec; 143(4):588-600. PubMed ID: 24943264
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HLA-A(*)0201(+) plasmacytoid dendritic cells provide a cell-based immunotherapy for melanoma patients.
    Aspord C; Leccia MT; Salameire D; Laurin D; Chaperot L; Charles J; Plumas J
    J Invest Dermatol; 2012 Oct; 132(10):2395-2406. PubMed ID: 22696054
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Co-ordinated regulation of plasmacytoid dendritic cell surface receptors upon stimulation with herpes simplex virus type 1.
    Schuster P; Donhauser N; Pritschet K; Ries M; Haupt S; Kittan NA; Korn K; Schmidt B
    Immunology; 2010 Feb; 129(2):234-47. PubMed ID: 19824924
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Generation of an Oncolytic Herpes Simplex Virus 1 Expressing Human MelanA.
    Boscheinen JB; Thomann S; Knipe DM; DeLuca N; Schuler-Thurner B; Gross S; Dörrie J; Schaft N; Bach C; Rohrhofer A; Werner-Klein M; Schmidt B; Schuster P
    Front Immunol; 2019; 10():2. PubMed ID: 30723467
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Review: dendritic cell immunotherapy for melanoma.
    Hadzantonis M; O'Neill H
    Cancer Biother Radiopharm; 1999 Feb; 14(1):11-22. PubMed ID: 10850282
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Herpes simplex virus type-1 induces IFN-alpha production via Toll-like receptor 9-dependent and -independent pathways.
    Hochrein H; Schlatter B; O'Keeffe M; Wagner C; Schmitz F; Schiemann M; Bauer S; Suter M; Wagner H
    Proc Natl Acad Sci U S A; 2004 Aug; 101(31):11416-21. PubMed ID: 15272082
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
    Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J
    J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oncolytic virotherapy for malignant melanoma with herpes simplex virus type 1 mutant HF10.
    Watanabe D; Goshima F; Mori I; Tamada Y; Matsumoto Y; Nishiyama Y
    J Dermatol Sci; 2008 Jun; 50(3):185-96. PubMed ID: 18226503
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TLR7 agonist 852A inhibition of tumor cell proliferation is dependent on plasmacytoid dendritic cells and type I IFN.
    Inglefield JR; Dumitru CD; Alkan SS; Gibson SJ; Lipson KE; Tomai MA; Larson CJ; Vasilakos JP
    J Interferon Cytokine Res; 2008 Apr; 28(4):253-63. PubMed ID: 18439103
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Skin-test infiltrating lymphocytes early predict clinical outcome of dendritic cell-based vaccination in metastatic melanoma.
    Aarntzen EH; Bol K; Schreibelt G; Jacobs JF; Lesterhuis WJ; Van Rossum MM; Adema GJ; Figdor CG; Punt CJ; De Vries IJ
    Cancer Res; 2012 Dec; 72(23):6102-10. PubMed ID: 23010076
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Implantable melanoma vaccine enters human clinical trials.
    Nagda P
    Immunotherapy; 2013 Dec; 5(12):1277. PubMed ID: 24422231
    [No Abstract]   [Full Text] [Related]  

  • 14. Plasmacytoid dendritic cell reconstitution following bone marrow transplantation: subnormal recovery and functional deficit of IFN-alpha/beta production in response to herpes simplex virus.
    Giraud S; Dhedin N; Gary-Gouy H; Lebon P; Vernant JP; Dalloul A
    J Interferon Cytokine Res; 2005 Mar; 25(3):135-43. PubMed ID: 15767787
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gaining ground on a cure through synergy: combining checkpoint inhibitors with cancer vaccines.
    Vreeland TJ; Clifton GT; Herbert GS; Hale DF; Jackson DO; Berry JS; Peoples GE
    Expert Rev Clin Immunol; 2016 Dec; 12(12):1347-1357. PubMed ID: 27323245
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive T Cell Therapy.
    Spranger S; Dai D; Horton B; Gajewski TF
    Cancer Cell; 2017 May; 31(5):711-723.e4. PubMed ID: 28486109
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of antigen-specific cytotoxic T lymphocytes by fusion cells generated from allogeneic plasmacytoid dendritic and tumor cells.
    Koido S; Homma S; Kan S; Takakura K; Namiki Y; Kobayashi H; Ito Z; Uchiyama K; Kajihara M; Arihiro S; Arakawa H; Okamoto M; Ohkusa T; Gong J; Tajiri H
    Int J Oncol; 2014 Jul; 45(1):470-8. PubMed ID: 24819411
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasmacytoid dendritic cells, a role in neoplastic prevention and progression.
    Lombardi VC; Khaiboullina SF; Rizvanov AA
    Eur J Clin Invest; 2015 Jan; 45 Suppl 1():1-8. PubMed ID: 25524580
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Type I IFN signaling on dendritic cells is required for NK cell-mediated anti-tumor immunity.
    Karimi K; Karimi Y; Chan J; Boudreau JE; Basset J; Chew MV; Reid S; Bramson JL; Wan Y; Ashkar AA
    Innate Immun; 2015 Aug; 21(6):626-34. PubMed ID: 25749844
    [TBL] [Abstract][Full Text] [Related]  

  • 20. From Melanoma Development to RNA-Modified Dendritic Cell Vaccines: Highlighting the Lessons From the Past.
    Shadbad MA; Hajiasgharzadeh K; Derakhshani A; Silvestris N; Baghbanzadeh A; Racanelli V; Baradaran B
    Front Immunol; 2021; 12():623639. PubMed ID: 33692796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.